Azer-cel is a Potential First-in Class Allogeneic CAR T Product Candidate for CD19+ CAR T Relapsed Patients
Azer-cel continues to demonstrate promising results in DLBCL patients who relapsed following CAR T, and we are encouraged by the high overall response rates with molecular remissions in this patient setting. Based on Phase 1b data, azer-cel has the potential to improve outcomes in this large and growing population with high unmet need.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma (NHL) that develops from the B-cells in the lymphatic system, which are responsible for producing antibodies typically to fight infectious disease.
DLBCL develops when some of your B-cells become cancerous. They grow uncontrollably, are abnormal, and do not die when they should.
DLBCL is the most common subtype of non-Hodgkin lymphoma (80.5k diagnosis per year) accounting for ~30% of all cases.
DLBCL can occur at any age but is most common in people aged over 50 years. The average age of diagnosis is 60-65 years; however, DLBCL can also affect children.
DLBCL is high-grade (fast-growing) and needs to be treated quickly.
Survival rates are poor with a high unmet clinical need.